SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Claris Life gets EU nod for anaesthetic drug

02 Jun 2011 Evaluate

Claris Lifesciences Ltd has received an in-principle approval for its anaesthetic drug Propofol in the European Union (EU), enabling the company to process its registration across 25 countries in the Union. Propofol, a flagship product of Claris, is an anaesthetic drug replacing other similar products, as recovery from Propofol is faster.

Europe has one of the most complex procedures for obtaining regulatory approvals. Claris is one of the few companies to have received approval for Propofol in Europe. The market size for Propofol is estimated to be at $750 million worldwide and $150 million in the EU. This registration will benefit Claris as EU is a lucrative market both in terms of revenue and margins.

crackcrack
Peers
Company Name CMP
Redington 227.50
Adani Enterprises 2228.00
Amrapali Industries 17.36
Rashi Peripheral 474.40
PDS 294.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×